Bosutinib: A SRC-ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia

Pharmacogenomics and Personalized Medicine

Volumn 6, Issue 1, 2013, Pages 57-62

  El Rassi, Fuad ^a   Khoury, Hanna Jean ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bosutinib; Chronic myeloid leukemia; Clinical activity; Review; SRC ABL kinase inhibitor; Treatment

Indexed keywords

ANTIDIARRHEAL AGENT; ATROPINE PLUS DIPHENOXYLATE; BOSUTINIB; DASATINIB; IMATINIB; KETOCONAZOLE; LANSOPRAZOLE; LOPERAMIDE; NILOTINIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; RIFAMPICIN;

ABDOMINAL PAIN; ACNE; ANEMIA; AREA UNDER THE CURVE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; CYTOPENIA; DIARRHEA; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FLUID RETENTION; FOLLICULITIS; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HEART DISEASE; HUMAN; LIVER FUNCTION TEST; LUNG EDEMA; MACULOPAPULAR RASH; MAXIMUM PLASMA CONCENTRATION; MUSCLE SPASM; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NEUTROPENIA; PANCYTOPENIA; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PLEURA EFFUSION; QUALITY OF LIFE; RASH; REVIEW; SIDE EFFECT; SKIN ALLERGY; SKIN EXFOLIATION; SKIN TOXICITY; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; UNITED STATES; VOMITING;

EID: 84881296045     PISSN: None     EISSN: 11787066     Source Type: Journal    
DOI: 10.2147/PGPM.S32145     Document Type: Review

References (27)

1. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341(3): 164-172.
2. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340(17): 1330-1340.
3. Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med. 2006;145(12):913-923.
4. Jemal A, Siegel R, Ward E, etal. Cancer statistics, 2006. CA Cancer J Clin. 2006;56(2):106-130.
5. Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012;118(12):3123-3127.
6. SEER Cancer Statistics Review, 1975-2006, [webpage on the Internet]. Bethesda, MD: National Cancer Institute; 2008; [cited 04/16/2012]. Available from: http://seer.cancer.gov/csr/1975-2006/. Accessed 06/11/2013.
7. Hughes TP, Hochhaus A, Branford S, etal. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010;116(19):3758-3765.
8. Kloke O, Opalka B, Niederle N. Interferon alfa as primary treatment of chronic myeloid leukemia: long-term follow-up of 71 patients observed in a single center. Leukemia. 2000;14(3):389-392.
9. Bonifazi F, de Vivo A, Rosti G, etal. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood. 2001;98(10):3074-3081.
10. O'Brien SG, Guilhot F, Larson RA, etal. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994-1004.
11. Björkholm M, Ohm L, Eloranta S, etal. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol. 2011;29(18):2514-2520.
12. US Food and Drug Administration. Imatinib. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf. Accessed March 19, 2013.
13. US Food and Drug Administration. FDA grants accelerated approval of a new dosing regimen of dasatinib (Sprycel). [press release]. Silver Spring, MD: US Food and Drug Administration; 2007 [November 13]. Available from: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm129236.htm. Accessed March 19, 2013.
14. US Food and Drug Administration. Nilotinib (Tasigna). Available at: [press release]. Silver Spring, MD: US Food and Drug Administration; 2010 [June 18]. Available from: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm216218.htm. Accessed March 19, 2013.
15. US Food and Drug Administration. Ponatinib. [press release]. Silver Spring, MD: US Food and Drug Administration; 2012 [December 17]. Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm332368.htm. Accessed March 23, 2013.
16. US Food and Drug Administration. Bosutinib tablets. [press release]. Silver Spring, MD: US Food and Drug Administration; 2012 [September 5]. Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm318203.htm. Accessed March 17, 2013.
17. Puttini M, Coluccia AM, Boschelli F, etal. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 2006;66(23):11314-11322.
18. Remsing Rix LL, Rix U, Colinge J, etal. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia. 2009;23(3):477-485.
19. Abbas R, Hug BA, Leister C, Gaaloul ME, Chalon S, Sonnichsen D. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects. Cancer Chemother Pharmacol. 2012;69(1):221-227.
20. Cortes JE, Kantarjian HM, Brümmendorf TH, etal. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011;118(17):4567-4576.
21. Khoury HJ, Cortes JE, Kantarjian HM, etal. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood. 2012;119(15):3403-3412.
22. Cortes JE, Kim DW, Kantarjian HM, etal. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30(28):3486-3492.
23. Gambacorti-Passerini C, Khoury HJ, etal. Safety and efficacy of BOS in patients with AP and BP CML and Ph+ ALL following resistance/intolerance to IM and other TKIs: update from study SKI-200. Presented at the American Society of Clinical Oncology; June 4-8, 2010; Chicago, IL, USA. Abstract 6509.
24. Gambacorti-Passerini C, Brummendorf TH, Cortes JE, etal. Evolution of bosutinib (BOS) toxicity in patients (pts) with Ph+ leukemia after resistance/intolerance to prior therapy. Presented at the American Society of Clinical Oncology; May 31-June 4, 2013; Chicago, IL, USA.
25. Khoury HJ, Cortes JE, Gambacorti-Passerini C, et al. Activity of bosutinib by baseline and emergent mutation status in Philadelphia chromosome-positive leukemia patients with resistance or intolerance to other tyrosine kinase inhibitors. Presented at the Annual Meeting of the American Society of Hematology; December 11, 2011; San Diego, CA, USA.
26. Redaelli S, Mologni L, Rostagno R, et al. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Am J Hematol. 2012;87:E125-E128.
27. Trask PC, Cella D, Besson N, Kelly V, Masszi T, Kim DW. Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia. Leuk Res. 2012;36(4):438-442.